The global stroke prevention in atrial fibrillation (SPAF) treatment market is expected to grow from USD 3.2 billion in 2021 to USD 4.8 billion by 2030, at a CAGR of 5.6% during the forecast period. The major factors driving the growth of this market are increasing prevalence of AF and increasing awareness about stroke risk factors among people with AF, which is leading to increased adoption of SPAF treatment globally. However, high cost associated with these treatments may hamper the growth of this market during the forecast period.
Some Of The Growth Factors Of This Market:
- Increasing prevalence of cardiovascular diseases and increasing awareness about the risk factors for stroke are some of the major drivers for this market growth.
- Increasing number of patients suffering from atrial fibrillation and increasing incidence rates are some other factors driving this market growth.
- North America is expected to be the largest regional Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market with a share of 39% by 2025.
Industry Growth Insights published a new data on “Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market”. The research report is titled “Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market research by Types (Oral Direct Thrombin Inhibitors, Oral Direct Factor Xa Inhibitors), By Applications (Hospitals, Clinics, Ambulatory Surgical Centers), By Players/Companies Boehringer Ingelheim, Bayer, Johnson & Johnson, Bristol-Myers Squibb, Pfizer, Daiichi-Sankyo, Gilead”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Research Report
By Type
Oral Direct Thrombin Inhibitors, Oral Direct Factor Xa Inhibitors
By Application
Hospitals, Clinics, Ambulatory Surgical Centers
By Companies
Boehringer Ingelheim, Bayer, Johnson & Johnson, Bristol-Myers Squibb, Pfizer, Daiichi-Sankyo, Gilead
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
233
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
 Treatment Industry Outlook.svg)
Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Report Segments:
The global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market is segmented on the basis of:
Types
Oral Direct Thrombin Inhibitors, Oral Direct Factor Xa Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Ambulatory Surgical Centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Boehringer Ingelheim
- Bayer
- Johnson & Johnson
- Bristol-Myers Squibb
- Pfizer
- Daiichi-Sankyo
- Gilead
 Treatment Market Overview.svg)
Highlights of The Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral Direct Thrombin Inhibitors
- Oral Direct Factor Xa Inhibitors
- By Application:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Treatment Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Stroke prevention in atrial fibrillation (SPAF) treatment is the goal of reducing the risk of stroke in patients with this condition. The most important way to reduce your risk of stroke is to have regular blood pressure and cholesterol screenings, and to get regular exercise. If you have SPAF, it is also important to follow your doctor's instructions for treating the condition.
Some of the major players in the stroke prevention in atrial fibrillation (spaf) treatment market are Boehringer Ingelheim, Bayer, Johnson & Johnson, Bristol-Myers Squibb, Pfizer, Daiichi-Sankyo, Gilead.
The stroke prevention in atrial fibrillation (spaf) treatment market is expected to register a CAGR of 5.6%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market - Supply Chain
4.5. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Forecast
4.5.1. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Absolute $ Opportunity
5. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Volume Forecast by Type
5.3.1. Oral Direct Thrombin Inhibitors
5.3.2. Oral Direct Factor Xa Inhibitors
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Ambulatory Surgical Centers
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Demand Share Forecast, 2019-2026
9. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Ambulatory Surgical Centers
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Volume Forecast by Type
9.7.1. Oral Direct Thrombin Inhibitors
9.7.2. Oral Direct Factor Xa Inhibitors
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Demand Share Forecast, 2019-2026
10. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Ambulatory Surgical Centers
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Volume Forecast by Type
10.7.1. Oral Direct Thrombin Inhibitors
10.7.2. Oral Direct Factor Xa Inhibitors
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Demand Share Forecast, 2019-2026
11. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Ambulatory Surgical Centers
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Volume Forecast by Type
11.7.1. Oral Direct Thrombin Inhibitors
11.7.2. Oral Direct Factor Xa Inhibitors
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Demand Share, 2019-2026
12. Asia Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Ambulatory Surgical Centers
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Volume Forecast by Type
12.7.1. Oral Direct Thrombin Inhibitors
12.7.2. Oral Direct Factor Xa Inhibitors
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Demand Share, 2019-2026
13. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Ambulatory Surgical Centers
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size and Volume Forecast by Type
13.7.1. Oral Direct Thrombin Inhibitors
13.7.2. Oral Direct Factor Xa Inhibitors
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market: Market Share Analysis
14.2. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Distributors and Customers
14.3. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Boehringer Ingelheim
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bayer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Johnson & Johnson
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Bristol-Myers Squibb
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Pfizer
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Daiichi-Sankyo
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Gilead
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
